Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Ticker
$ABEO
Sector
Primary listing
Employees
226
Headquarters
Website
ABEO Metrics
BasicAdvanced
$322m
6.18
$0.91
1.34
-
Price and volume
Market cap
$322m
Beta
1.34
52-week high
$7.54
52-week low
$4.00
Average daily volume
1.1m
Financial strength
Current ratio
5.894
Quick ratio
5.636
Long term debt to equity
5.911
Total debt to equity
15.988
Interest coverage (TTM)
-25.97%
Profitability
EBITDA (TTM)
-90.049
Gross margin (TTM)
-123.84%
Net profit margin (TTM)
454.86%
Operating margin (TTM)
-637.92%
Effective tax rate (TTM)
0.15%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-38.93%
Return on equity (TTM)
70.99%
Valuation
Price to earnings (TTM)
6.18
Price to revenue (TTM)
21.241
Price to book
2.22
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-3.623
Free cash flow yield (TTM)
-27.60%
Free cash flow per share (TTM)
-1.559
Growth
Earnings per share change (TTM)
-196.56%
3-year revenue growth (CAGR)
138.78%
10-year revenue growth (CAGR)
30.47%
3-year earnings per share growth (CAGR)
-31.71%
10-year earnings per share growth (CAGR)
-24.24%
ABEO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs